// App-Quantinova.ai

22 : Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Researchers

Presenter

  • David J. Kuter

Principal Investigators

  • Merlin Efraim

  • Jiri Mayer

  • Vickie McDonald

  • Robert J. Bird

  • Thomas Regenbogen

  • Mamta Garg

  • Zane Kaplan

  • Olga Bandman

  • Regan Burns

  • Ann Neale

  • Dolca Thomas

  • Nichola Cooper

Medical Centers

  • Nephrology Division, Massachusetts General Hospital, Boston, MA

  • Multiprofile Hospital for Active Treatment Sv. Marina , Varna, Bulgaria

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom

  • Gastroenterology & Hepatology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

  • MidMichigan Medical Center, Midland, MI

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • Monash Newborn, Monash Medical Centre, Clayton, Victoria, Australia

  • Principia Biopharma, South San Francisco, CA

  • Department of Medicine, St. Thoma- Hospital, London, United Kingdom

Locations

  • United States

  • Bulgaria

  • Czech Republic

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved